ArticleCureus2026
Precision Health Optimization Program in the Management of Advanced Parkinson's Disease: A Case Series.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is reported to be the fastest-growing neurodegenerative condition with significant management challenges. Neurobiology is linked to mitochondrial dysfunction, oxidative stress, autonomic imbalance, and neuroinflammation. There is progressive propagation of alpha-synuclein protein in neural networks and dopamine deficiency in the nigrostriatal pathway. Levodopa remains the gold standard agent in its management. However, the non-motor symptoms that significantly compromise quality of life remain largely unresponsive to levodopa. Currently, there are no interventions that can modify disease progression. Following a comprehensive assessment by an interdisciplinary team, three patients with advanced idiopathic PD were treated with a precision health optimization program. The program included dual stellate ganglion block, nutraceutical infusions, and extracorporeal blood ozone therapy. The program targets the underlying autonomic imbalance, oxidative stress, neural inflammation, and mitochondrial dysfunction. Validated outcome measures were completed at baseline and at the 12-week review. At the 12-week review following the program, all three patients reported a reduction in disease severity with an improvement in quality of life. The innovative precision health optimization program could have a role in the management of advanced PD. Limitations include a small patient cohort, the absence of a control arm, and potential placebo effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.